* Daily Basal Insulins: The primary shift will be patients moving away from once-daily basal insulins, such as insulin glargine, to this new once-weekly alternative
Most current evidence is limited to 5272 weeks of exposure [4]
This is a study average, not a prediction of your personal result
It can interact with Insulin, Sulfonylureas, and oral medicines affected by delayed stomach emptying
Disclosure Fernando Gomez-Peralta has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly, has taken part in advisory boards for Sanofi, Novo Nordisk, and AstraZeneca Pharmaceuticals LP, and has acted as a speaker for Sanofi, Novo Nordisk, Boehringer Ingelheim, Novartis, Bristol-Myers Squibb Company, Eli Lilly, and AstraZeneca Pharmaceuticals LP